A summary of the renal cancer session of the Conversations & Trending Topics in GU Cancers conference in the Canary Islands. Monty Pal, MD, FASCO, discusses his recent study on the use of novel CAR T-cell therapy for renal cell carcinoma. David McDermott, MD, debates the role of ipilimumab for clear cell renal cancer with Uromigos host Brian Rini, MD. Pavlos Msaouel chats with The Uromigos about his editorial on the results of the recent COSMIC-313 trial. The Uromigos chat with Dan Shapiro, Assistant Professor of Urologic Oncology, on his work in renal medullary carcinoma. The Uromigos chat with Scott M. Haake for the second episode of their Rising Star series and discuss his latest project. The Rising Star series starts with Renee Saliby, a postdoctoral GU oncology research fellow at Dana-Farber Cancer Institute. Toni Choueiri describes the COSMIC-313 trial on cabozantinib with nivolumab and ipilimumab in advanced or metastatic RCC. Bernard Escudier, MD, joins The Uromigos to talk about his career development and work in the field of kidney cancer. Kimryn Rathmell, MD, PhD, discusses highlights from the kidney cancer guidelines presented at the ASCO Annual Meeting. Darren Feldman describes different approaches to relapsed germ cell tumors and the TIGER study. David Braun gives an overview of the mechanisms of response to PD1 therapy in renal cancer. Michael Staehler gives an overview of the abstracts presented in the oral session from EIKCS 2022. Dr. David McDermott attempts to get his point across he discusses favorable risk clear cell renal cancer and its treatments. Dr. Laurence Albiges gives an overview of the new ESMO RCC guidelines, and Brian challenges her and Tom. Dr. David Cella unpacks the data across these studies and makes some conclusions. Dr. David McDermott describes his clinical cancer research paper on treatment-free survival in kidney cancer. Chad Tang discusses his oncology paper recently published in Lancet. Tom and Brian take a look back at the year in kidney cancer with Dr. Toni Choueiri. Dr. Mike Atkins discusses the role of CTLA4 inhibition in RCC.